Incanthera is quoted on the Aquis Stock Exchange's Apex segment rather than AIM or the London Stock Exchange's Main Market, a detail worth noting given how often small-cap coverage assumes an AIM listing by default. At this scale, with a market capitalisation of roughly …
ProBiotix Health develops clinically studied probiotic ingredients, particularly for cardiovascular and cholesterol-related health, and licenses these formulations to partners around the world rather than selling directly to consumers. Through the first half of 2026 the company confirmed a string of new international partnerships, including …
On 25 August 2026, BSF Enterprise confirmed that Indigo Capital Investments had converted £100,283 of the outstanding balance under the company's £1 million convertible loan note facility, resulting in the issue of 10 million new ordinary shares at 1 penny each. The new shares …
The headline growth figures were modest but improving. Like-for-like netRevenuerose 2.6% in the first half, with the core Reckitt (LSE:RKT) portfolio up 2.7%, but the more important detail was the trajectory: core like-for-like growth accelerated to 4.2% in the second quarter from just 1.3% …
Toscafund first tabled its 250p proposal in mid-May 2026, sending Spire's shares sharply higher, and has since spent months conductingDue Diligenceand arranging financing. Under the UK Takeover Code, a potential bidder must, by a set deadline, either announce a firm intention to bid or …
The proximate cause was geography. First-half revenue rose only about 10% on a reported basis (roughly 12% at constant currency), well short of what the market had been modelling. Sales in China fell around 16%, hit by tighter export-control restrictions and a reorganisation of …
Haleon delivered a stronger second quarter in the first half of 2026, with growth accelerating as its oral-health powerhouses Sensodyne and Parodontax led the charge. The consumer-health group — spun out of GSK in 2022 and home to brands including Panadol, Centrum, Voltaren and …
GSK's pipeline momentum has become the central pillar of itsInvestmentcase, and 2026 has brought a steady drumbeat of regulatory and clinical progress. A notable milestone came at the start of the year, when Japan's Ministry of Health, Labour and Welfare approved Exdensur (depemokimab) on …
For aBusinessthat reported just £8.6m of cash at 31 October 2025 and a runway only into the second half of 2026, the change is substantial. The question now is whether Scancell can execute a 550-patient global trial, close a complex cross-border transaction and deliver …
Yet the shares trade at around 31p, below the placing price, valuing the Cambridge-basedBusinessat roughly £16.7m. The question for investors is whether the 2025 recovery in order intake converts into sustained growth, and whether new healthcare and consumer wellness initiatives, including a 45,000-participant study …